ArticleCirculation research2018
Impaired Production and Diurnal Regulation of Vascular RvD
Open access · hybridAbstract read
In one paragraph
Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Circadian clock regulation of hemostasis: a systematic review of molecular pathways.Research and practice in thrombosis and haemostasis · 2026Pooled it
- Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Trial
- Restoration of circadian rhythm as novel targets against sarcopenia.Chinese medical journal · 2026Review
- Molecular Dynamics and Free Energy Calculations Predict Binding Mode and Affinity Determinants of Specialized Pro-Resolving Mediators at GPR101.ACS omega · 2026Article
- Maresin 1 modulates renal and cardiac lipid profiles in hypertensive rats.American journal of physiology. Renal physiology · 2025Article
- Potential and Future Therapeutic Applications of Eicosapentaenoic/Docosahexaenoic Acid and Probiotics in Chronic Low-Grade Inflammation.Biomedicines · 2025Review
- Resolution of inflammation increases erythropoiesis.Blood red cells & iron · 2025Article
- Dynamics of Fatty Acid Composition in Lipids and Their Distinct Roles in Cardiometabolic Health.Biomolecules · 2025Review
- Targeting Inflammatory Imbalance in Chronic Kidney Disease: Focus on Anti-Inflammatory and Resolution Mediators.International journal of molecular sciences · 2025Review
- Editorial Note: Prolonged immune alteration following resolution of acute inflammation in humans.PloS one · 2025Article
- Development and Validation of Methodologies for the Identification of Specialized Pro-Resolving Lipid Mediators and Classic Eicosanoids in Biological Matrices.Journal of the American Society for Mass Spectrometry · 2024Article
- Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.Metabolites · 2024Review
- Omega-3 (Nutrients · 2024Review
- Article
- The potential role of n-3 fatty acids and their lipid mediators on asthmatic airway inflammation.Frontiers in immunology · 2024Review
- Disrupted balance between pro-inflammatory lipid mediators and anti-inflammatory specialized pro-resolving mediators is linked to hyperinflammation in patients with alcoholic hepatitis.Frontiers in immunology · 2024Article
- Prolonged experimental sleep disturbance affects the inflammatory resolution pathways in healthy humans.Brain, behavior, and immunity · 2023Article
- Genetically Predicted Levels of Serum Metabolites and Risk of Sarcopenia: A Mendelian Randomization Study.Nutrients · 2023Article
- Resolvins and cysteinyl-containing pro-resolving mediators activate resolution of infectious inflammation and tissue regeneration.Prostaglandins & other lipid mediators · 2023Review
- Immunomodulation of periodontitis with SPMs.Frontiers in oral health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Romain A ColasFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Patricia R SouzaFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Mary E WalkerFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Maudrian BurtonFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Zbigniew ZasłonaFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Annie M CurtisFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Raquel M MarquesFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.).
Jesmond DalliFrom the Lipid Mediator Unit, William Harvey Research Institute (R.A.C., P.R.S., M.E.W., R.M.M., J.D.) NIHR Cardiovascular Biomedical Research Unit at Barts (M.B.), and the Centre for Inflammation and Therapeutic Innovation (J.D.), Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland (Z.Z.); and Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin (A.M.C.). j.dalli@qmul.ac.uk.
Trinity College Dublin · IE
Funding
Department of HealthEuropean Research Council 677542Medical Research Council MR/J015741/1Wellcome Trust 101604/Z/13/ZWellcome Trust 107613
Abstract
rationaleDiurnal mechanisms are central to regulating host responses. Recent studies uncovered a novel family of mediators termed as specialized proresolving mediators that terminate inflammation without interfering with the immune response.
objectiveHerein, we investigated the diurnal regulation of specialized proresolving mediators in humans and their role in controlling peripheral blood leukocyte and platelet activation. METHODS AND
resultsUsing lipid mediator profiling and healthy volunteers, we found that plasma concentrations of n-3 docosapentaenoic acid-derived D-series resolvins (RvD
conclusionsThese results demonstrate that peripheral blood RvD
Indexed as
Circadian RhythmAdenosineAnimalsBlood PlateletsFatty Acids, UnsaturatedHumansInflammationLeukocytesLipoxygenaseMiceMyocardial InfarctionThromboxane B2Adenosinedocosapentaenoic acidFatty Acids, UnsaturatedLipoxygenaseThromboxane B2adenosineeicosanoidslipoxygenasemonocyteneutrophilsplatelets
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.